Non-Hodkins Lymphoma

≥ 18 Yrs

CCT5012
Phase III
Axicabtagene Ciloleucel vs SoC Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
PI: Miklos Kite Pharma

CCT5006-EXP
Expanded Access Axicabtagene Ciloleucel in Tx Relapsed/Refractory T-plant-Ineligible Aggressive NHL
PI: Miklos Kite Pharma

CCT5016
Managed Access Program (MAP) CTL019 in ALL or DLBCL
PI: Miklos Sponsor: Pending

CCT5001
Phase I
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Recurrent/Refractory B-Cell Malignancies
PI: Miklos Stanford

Priority: 1st

CCT5024
Phase I/II
ALLO-501 (AntiCD19 Allogeneic CAR TCell Tx) Relapsed/Refractory LargeB-Cell & Follicular Lymphoma
PI: Miklos Sponsor: Pending

Priority: 2nd

CCT5020
Phase Ib
Tisagenlecleucel in Combo w/Ibrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
PI: Miklos Sponsor: Pending

Priority: 3rd

CCT5018
Phase I/II
Axicabtagene Ciloleucel in Combo w/ Utomilumab in Refractory Large B-Cell Lymphoma
PI: Miklos Sponsor: Pending

Priority: 4th

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu